A new analysis of data from the phase 3 STEP (semaglutide treatment effect in people with obesity) trials shows that adults using Wegovy for obesity treatment were more likely to discontinue or reduce the intensity of their antihypertensive and lipid-lowering medications compared to those on a placebo.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
